Minerva Neurosciences Stock News

WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv

Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreemen

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. BBQ Holdings, Inc. (NAS

Gainers Assure Holdings Corp. (NASDAQ: IONM) shares jumped 88.8% to $3.9650 after jumping around 104% on Thursday. Cooper-Standard Holdings Inc. (NYSE: CPS) rose 70.4% to $8.57 following better-than-

Gainers Assure Holdings Corp. (NASDAQ: IONM) shares rose 141.4% to $5.07 in pre-market trading after jumping around 104% on Thursday. Marker Therapeutics, Inc. (NASDAQ: MRKR) shares rose 119% to $0.7

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per sh

Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday. Onion Global Limited (NYSE: OG) gained 113.9% to $0.8556. ChemoCentryx,

Gainers Tenax Therapeutics, Inc. (NASDAQ: TENX) rose 90.1% to $0.59 in pre-market trading after dipping more than 46% on Friday. Epizyme, Inc. (NASDAQ: EPZM) rose 57.2% to $1.50 in pre-market tradi

Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter of 2022 Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarte

The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.

Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.

Minerva Neurosciences Inc (NASDAQ: NERV) received the official meeting minutes from the Type C meeting with the FDA regarding the development of roluperidone for negative symptoms in schizophrenia.

Company to Host Webcast Wednesday, April 13, 2022 at 11am ET Company to Host Webcast Wednesday, April 13, 2022 at 11am ET

Volume-weighted average price, or VWAP, is the ratio of total volume traded divided by the total volume traded for a chosen time frame. VWAP is an important indicator for intraday trading, as it grap

AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.